These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12452435)

  • 21. [Metabolism of drugs. III. Genetic factors inducing and inhibiting metabolism].
    Dyderski S; Grzymisławski M
    Pol Merkur Lekarski; 2005 Apr; 18(106):457-61. PubMed ID: 16161934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A basic conceptual and practical overview of interactions with highly prescribed drugs.
    Dresser GK; Bailey DG
    Can J Clin Pharmacol; 2002; 9(4):191-8. PubMed ID: 12584577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs.
    Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
    Acta Pol Pharm; 2008; 65(3):307-18. PubMed ID: 18646550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-associated disease: cytochrome P450 interactions.
    Mann HJ
    Crit Care Clin; 2006 Apr; 22(2):329-45, vii. PubMed ID: 16678003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.
    Masubuchi Y; Horie T
    Crit Rev Toxicol; 2007 Jun; 37(5):389-412. PubMed ID: 17612953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes of AC/cAMP system and phosphorylation regulation of adenylate cyclase activity in brain regions from morphine-dependent mice].
    Fang F; Wang Q; Cao Q; Liu J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):14-9. PubMed ID: 12903486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
    Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T
    J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown.
    Alfaro CL
    Psychopharmacol Bull; 2001; 35(4):80-93. PubMed ID: 12397858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of cerebral and hepatic cytochrome P450s alters behavioral activity of rat offspring following prenatal exposure to lindane.
    Johri A; Yadav S; Dhawan A; Parmar D
    Toxicol Appl Pharmacol; 2007 Dec; 225(3):278-92. PubMed ID: 17919674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against Trp-P-2 DNA adduct formation in C57bl6 mice by purpurin is accompanied by induction of cytochrome P450.
    Marczylo T; Sugiyama C; Hayatsu H
    J Agric Food Chem; 2003 May; 51(11):3334-7. PubMed ID: 12744663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
    Bachmann KA; Lewis JD
    Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells.
    Obara Y; Labudda K; Dillon TJ; Stork PJ
    J Cell Sci; 2004 Dec; 117(Pt 25):6085-94. PubMed ID: 15546918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenylyl cyclase isoform-selective regulation of vascular smooth muscle proliferation and cytoskeletal reorganization.
    Gros R; Ding Q; Chorazyczewski J; Pickering JG; Limbird LE; Feldman RD
    Circ Res; 2006 Oct; 99(8):845-52. PubMed ID: 16973907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrochemically driven drug metabolism by membranes containing human cytochrome P450.
    Mie Y; Suzuki M; Komatsu Y
    J Am Chem Soc; 2009 May; 131(19):6646-7. PubMed ID: 19402636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A role for CYP in the drug-hormone crosstalk of the brain.
    Meyer RP; Gehlhaus M
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):675-87. PubMed ID: 20201748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytochrome P-450 isoenzymes as predictors of drug interactions].
    Pelkonen O
    Duodecim; 1994; 110(17):1575-9. PubMed ID: 7497987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.